N@N

Matthew Harrison Reiterated (SRPT) at Buy and Held Target at $183 on, Aug 3rd, 2023

Matthew Harrison of Morgan Stanley, Reiterated "Sarepta Therapeutics, Inc." (SRPT) at Buy and Held Target at $183 on, Aug 3rd, 2023.

Matthew has made no other calls on SRPT in the last 4 months.

There are 11 other peers that have a rating on SRPT. Out of the 11 peers that are also analyzing SRPT, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Gavin Clark-Gartner of "Evercore ISI Group" Downgraded from Buy to Hold and Held Target at $139 on, Friday, June 23rd, 2023
• Judah Frommer of "Credit Suisse" Reiterated at Hold and Held Target at $141 on, Friday, June 23rd, 2023

These are the ratings of the 9 analyists that currently disagree with Matthew

---

• Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $213 on, Friday, June 23rd, 2023
• Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $166 on, Friday, June 23rd, 2023
• Neena Bitritto-Garg of "Citigroup" Maintained at Strong Buy with Increased Target to $204 on, Friday, June 23rd, 2023
• Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $215 on, Friday, June 23rd, 2023
• Hartaj Singh of "Oppenheimer" Reiterated at Buy and Held Target at $180 on, Friday, May 26th, 2023
• Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $173 on, Monday, May 15th, 2023
• Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $176 on, Monday, May 15th, 2023
• David Hoang of "SMBC Nikko" Initiated at Buy and Held Target at $185 on, Wednesday, April 26th, 2023
• Uy Ear of "Mizuho" Reiterated at Strong Buy and Held Target at $160 on, Friday, April 14th, 2023

Contributing Sources

---